Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2026 07:38 ET | Source: Curium

Curium Announces Definitive Agreement to Merge with Lantheus

$8B Curium-Lantheus deal creates a global radiopharmaceutical leader, expanding reach across oncology, neurology and cardiology in 70+ countries.
July 30, 2026 02:00 ET | Source: Curium

Curium advances plans for second investment in Romania to expand access to advanced nuclear medicine

Curium advances plans for a second cyclotron in Romania, supporting greater access to PET imaging and nuclear medicine services.
July 27, 2026 08:00 ET | Source: Curium

Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs

Curium has reintroduced Thallium-201 in the U.S., restoring access to a key nuclear cardiology imaging agent.
June 29, 2026 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients

Patient enrollment has been completed; all enrolled patients remain aliveData presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium Garching/Munich and Münster, Germany...
June 01, 2026 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026

Analysis from the Phase 3 COMPETE trial suggests population-based modeling may enable accurate individualized dosimetry with substantially fewer imaging requirements Los Angeles, California, June 1,...
May 30, 2026 13:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotideData build upon previously reported COMPETE...
April 24, 2026 09:57 ET | Source: Precedence Research

Radiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market Demand

Ottawa, April 24, 2026 (GLOBE NEWSWIRE) -- Rising global incidence of cancer and cardiovascular diseases is driving demand for advanced diagnostic imaging and targeted radiopharmaceutical therapies....
April 21, 2026 10:30 ET | Source: ITM Isotope Technologies Munich SE

ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026

ITM today announced that it will provide quality of life data from its Phase 3 COMPETE trial in a poster presentation at ASCO 2026.
March 05, 2026 06:10 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Pancreatic Neuroendocrine Tumors at ENETS 2026 Conference

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with PNETs at ENETS 2026
February 25, 2026 08:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026

ITM today announced that it will provide further post-hoc subgroup analysis data focusing on Pancreatic Neuroendocrine Tumors from its Phase 3 trial